Cupps Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cupps Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10,390	Closed	-$834K	–	182
2015 Q3	$834K	Sell	10,390 -20,798	-67%	-$2.31M	0.11%	122
2015 Q2	$3.74M	Buy	31,188 +1,545	+5%	+$185K	0.36%	91
2015 Q1	$3.1M	Buy	29,643 +4,454	+18%	+$451K	0.28%	98
2014 Q4	$2.44M	Sell	25,189 -82,737	-77%	-$7.67M	0.22%	110
2014 Q3	$8.43M	Sell	107,926 -21,727	-17%	-$1.4M	0.78%	44
2014 Q2	$8.19M	Buy	129,653 +34,806	+37%	+$2.07M	0.66%	57
2014 Q1	$6.37M	Sell	94,847 -7,476	-7%	-$579K	0.49%	72
2013 Q4	$6.58M	Buy	102,323 +344	+0.3%	+$20.5K	0.45%	76
2013 Q3	$6.53M	Buy	+101,979	New	+$5.08M	0.42%	74

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cupps Capital Management's ALNY Position: Q4 2015 in Review

Cupps Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 10,390 shares — an estimated $834K sold.

Cupps Capital Management first reported a position in ALNY in Q3 2013 and held it in 9 quarters. The position peaked at $8.43M in Q3 2014. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

Cupps Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Cupps Capital Management sold 10,390 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $834K.
Cupps Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 9 quarters.
Cupps Capital Management's Alnylam Pharmaceuticals position peaked at $8.43M in Q3 2014.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on Cupps Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.